Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats

Hiroyuki Kaneda, Osamu Shirakawa, James Dale, Leslie Goodman, Susan E. Bachus, Carol A. Tamminga

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Vacuous chewing movements in rats may be an animal analogue of the human motor disorder, tardive dyskinesia. The movements are phenomenologically and pharmacologically similar to tardive dyskinesia. The pathophysiology of these involuntary oral movements, and perhaps of tardive dyskinesia, are likely to include both dopamine receptor changes, and alterations in GABA (γ-aminobutyric acid) system function. In an attempt to test the involvement of GAVA system dysfunction in these movements, we treated rats chronically with water alone, haloperidol alone, the GABA agonist progabide alone, and haloperidol plus progabide. Sprague-Dawley rats received haloperidol (1.5 mg/kg per day) in their drinking water and progabide (100 mg/kg per day) in their food for 12 months. After 12 months of treatment, haloperidol had induced vacuous chewing movements when administered alone, but the prevalence of the movements was decreased by 40% with the coadministration of progabide. Moreover, the haloperidol-progabide-treated animals did not merely demonstrate movement suppression but actual inhibition of movement onset, as determined by an additional progabide-withdrawal experiment. These data would suggest that progabide and perhaps other GABAmimetic compounds can prevent the development of tarkive dyskinesia in man.

Original languageEnglish (US)
Pages (from-to)43-49
Number of pages7
JournalEuropean Journal of Pharmacology
Volume212
Issue number1
DOIs
StatePublished - Feb 25 1992

Fingerprint

Movement Disorders
Haloperidol
Mastication
Dyskinesias
GABA Agonists
Aminobutyrates
Dopamine Receptors
progabide
Drinking Water
gamma-Aminobutyric Acid
Sprague Dawley Rats
Food
Water
Tardive Dyskinesia

Keywords

  • Haloperidol (chronic)
  • Progabide
  • Tardive dyskinesia
  • Vacuous chewing movements

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats. / Kaneda, Hiroyuki; Shirakawa, Osamu; Dale, James; Goodman, Leslie; Bachus, Susan E.; Tamminga, Carol A.

In: European Journal of Pharmacology, Vol. 212, No. 1, 25.02.1992, p. 43-49.

Research output: Contribution to journalArticle

Kaneda, Hiroyuki ; Shirakawa, Osamu ; Dale, James ; Goodman, Leslie ; Bachus, Susan E. ; Tamminga, Carol A. / Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats. In: European Journal of Pharmacology. 1992 ; Vol. 212, No. 1. pp. 43-49.
@article{99049c6e7efb434381dff4f5e2976f46,
title = "Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats",
abstract = "Vacuous chewing movements in rats may be an animal analogue of the human motor disorder, tardive dyskinesia. The movements are phenomenologically and pharmacologically similar to tardive dyskinesia. The pathophysiology of these involuntary oral movements, and perhaps of tardive dyskinesia, are likely to include both dopamine receptor changes, and alterations in GABA (γ-aminobutyric acid) system function. In an attempt to test the involvement of GAVA system dysfunction in these movements, we treated rats chronically with water alone, haloperidol alone, the GABA agonist progabide alone, and haloperidol plus progabide. Sprague-Dawley rats received haloperidol (1.5 mg/kg per day) in their drinking water and progabide (100 mg/kg per day) in their food for 12 months. After 12 months of treatment, haloperidol had induced vacuous chewing movements when administered alone, but the prevalence of the movements was decreased by 40{\%} with the coadministration of progabide. Moreover, the haloperidol-progabide-treated animals did not merely demonstrate movement suppression but actual inhibition of movement onset, as determined by an additional progabide-withdrawal experiment. These data would suggest that progabide and perhaps other GABAmimetic compounds can prevent the development of tarkive dyskinesia in man.",
keywords = "Haloperidol (chronic), Progabide, Tardive dyskinesia, Vacuous chewing movements",
author = "Hiroyuki Kaneda and Osamu Shirakawa and James Dale and Leslie Goodman and Bachus, {Susan E.} and Tamminga, {Carol A.}",
year = "1992",
month = "2",
day = "25",
doi = "10.1016/0014-2999(92)90070-K",
language = "English (US)",
volume = "212",
pages = "43--49",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats

AU - Kaneda, Hiroyuki

AU - Shirakawa, Osamu

AU - Dale, James

AU - Goodman, Leslie

AU - Bachus, Susan E.

AU - Tamminga, Carol A.

PY - 1992/2/25

Y1 - 1992/2/25

N2 - Vacuous chewing movements in rats may be an animal analogue of the human motor disorder, tardive dyskinesia. The movements are phenomenologically and pharmacologically similar to tardive dyskinesia. The pathophysiology of these involuntary oral movements, and perhaps of tardive dyskinesia, are likely to include both dopamine receptor changes, and alterations in GABA (γ-aminobutyric acid) system function. In an attempt to test the involvement of GAVA system dysfunction in these movements, we treated rats chronically with water alone, haloperidol alone, the GABA agonist progabide alone, and haloperidol plus progabide. Sprague-Dawley rats received haloperidol (1.5 mg/kg per day) in their drinking water and progabide (100 mg/kg per day) in their food for 12 months. After 12 months of treatment, haloperidol had induced vacuous chewing movements when administered alone, but the prevalence of the movements was decreased by 40% with the coadministration of progabide. Moreover, the haloperidol-progabide-treated animals did not merely demonstrate movement suppression but actual inhibition of movement onset, as determined by an additional progabide-withdrawal experiment. These data would suggest that progabide and perhaps other GABAmimetic compounds can prevent the development of tarkive dyskinesia in man.

AB - Vacuous chewing movements in rats may be an animal analogue of the human motor disorder, tardive dyskinesia. The movements are phenomenologically and pharmacologically similar to tardive dyskinesia. The pathophysiology of these involuntary oral movements, and perhaps of tardive dyskinesia, are likely to include both dopamine receptor changes, and alterations in GABA (γ-aminobutyric acid) system function. In an attempt to test the involvement of GAVA system dysfunction in these movements, we treated rats chronically with water alone, haloperidol alone, the GABA agonist progabide alone, and haloperidol plus progabide. Sprague-Dawley rats received haloperidol (1.5 mg/kg per day) in their drinking water and progabide (100 mg/kg per day) in their food for 12 months. After 12 months of treatment, haloperidol had induced vacuous chewing movements when administered alone, but the prevalence of the movements was decreased by 40% with the coadministration of progabide. Moreover, the haloperidol-progabide-treated animals did not merely demonstrate movement suppression but actual inhibition of movement onset, as determined by an additional progabide-withdrawal experiment. These data would suggest that progabide and perhaps other GABAmimetic compounds can prevent the development of tarkive dyskinesia in man.

KW - Haloperidol (chronic)

KW - Progabide

KW - Tardive dyskinesia

KW - Vacuous chewing movements

UR - http://www.scopus.com/inward/record.url?scp=0026502737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026502737&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(92)90070-K

DO - 10.1016/0014-2999(92)90070-K

M3 - Article

C2 - 1555638

AN - SCOPUS:0026502737

VL - 212

SP - 43

EP - 49

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -